


Product Data Sheet

Fenofibrate

| | |
|------------------|--|
| Cat. No.: | B1943 |
| CAS No.: | 49562-28-9 |
| Formula: | C ₂₀ H ₂₁ ClO ₄ |
| M.Wt: | 360.83 |
| Synonyms: | |
| Target: | Metabolism |
| Pathway: | PPAR |
| Storage: | Store at -20°C |



Solvent & Solubility

insoluble in H₂O; ≥12.75 mg/mL in DMSO; ≥18.57 mg/mL in EtOH

| In Vitro | Preparing Stock Solutions | Mass | | | |
|----------|---------------------------|-----------------------|-----------|------------|------------|
| | | Solvent Concentration | 1mg | 5mg | 10mg |
| | | 1 mM | 2.7714 mL | 13.8569 mL | 27.7139 mL |
| | | 5 mM | 0.5543 mL | 2.7714 mL | 5.5428 mL |
| | | 10 mM | 0.2771 mL | 1.3857 mL | 2.7714 mL |

Please refer to the solubility information to select the appropriate solvent

Biological Activity

| | | |
|---------------------------|-----------------------------|---|
| Shortsummary | PPAR α agonist | |
| IC ₅₀ & Target | | |
| In Vitro | Cell Viability Assay | |
| | Cell Line: | MCF-7 and Panc-1 cells |
| | Preparation method: | The solubility of this compound in DMSO is > 12.8 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
| Reacting conditions: | 24, 48 and 72 hrs | |

| | | |
|---------|--------------------------|---|
| | Applications: | At 24th, 48th and 72th hrs, the IC50 values of Fenofibrate were 96.6, 46.5 and 9.2 µg/mL on Panc-1 cells, and 93.5, 55.9 and 8 µg/mL on MCF-7 cells, respectively. Compared with the untreated solvent control, MCF-7 and Panc-1 cells treated with 1/2 IC50, IC50 and 2 IC50 of Fenofibrate for 24 hrs exhibited a significant increase in the relative activity of caspase 3/7. |
| In Vivo | Animal experiment | |
| | Animal models: | Mice bearing Ehrlich ascites carcinoma (EAC) |
| | Dosage form: | 200 mg/kg/day; p.o.; for 18 days |
| | Applications: | In an EAC mouse model, Fenofibrate significantly reduced tumor weight and volume, without affecting the relative heart weight. However, Fenofibrate treatment significantly decreased the body weight and increased the relative liver weight. In addition, a marked decrease in the carcinoembryonic antigen (CEA) level was also observed in the Fenofibrate treatment group. |
| | Other notes: | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |

Product Citations

1. Wang L, Xie H, et al. "rSj16 Protects against DSS-Induced Colitis by Inhibiting the PPAR-α Signaling Pathway." *Theranostics*. 2017 Aug 15;7(14):3446-3460. PMID:28912887

See more customer validations on www.apexbt.com.

References

[1]. Sabaa M, ELFayoumi HM, Elshazly S, Youns M, Barakat W. Anticancer activity of salicin and fenofibrate. *Naunyn Schmiedeberg Arch Pharmacol*. 2017 Jul 21.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APEX BIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

